Zacks Small Cap Has Bearish Outlook for PLX FY2025 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Research analysts at Zacks Small Cap reduced their FY2025 earnings per share estimates for shares of Protalix BioTherapeutics in a report released on Monday, February 3rd. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings per share of $0.44 for the year, down from their prior forecast of $0.63. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.02 per share. Zacks Small Cap also issued estimates for Protalix BioTherapeutics’ FY2026 earnings at $0.84 EPS.

PLX has been the topic of a number of other reports. StockNews.com downgraded Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. HC Wainwright lifted their target price on Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday.

Protalix BioTherapeutics Price Performance

PLX stock opened at $2.52 on Wednesday. The company has a market cap of $185.55 million, a P/E ratio of -19.38 and a beta of 0.75. Protalix BioTherapeutics has a 1 year low of $0.82 and a 1 year high of $2.54. The stock’s fifty day moving average price is $2.01 and its 200-day moving average price is $1.43.

Hedge Funds Weigh In On Protalix BioTherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Y Intercept Hong Kong Ltd purchased a new position in Protalix BioTherapeutics during the fourth quarter valued at $35,000. XTX Topco Ltd purchased a new position in shares of Protalix BioTherapeutics in the third quarter valued at about $36,000. Cubist Systematic Strategies LLC purchased a new position in shares of Protalix BioTherapeutics in the second quarter valued at about $37,000. Sanctuary Advisors LLC purchased a new position in shares of Protalix BioTherapeutics in the third quarter valued at about $38,000. Finally, PFG Investments LLC purchased a new position in shares of Protalix BioTherapeutics in the fourth quarter valued at about $39,000. 16.53% of the stock is currently owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.